問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Study Site

Study Site



National Taiwan University Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 1,343

    Total Beds

  • 801

    Total Doctors

  • n123987ctc@gmail.com
  • Hsin-Pin Tu
  • 06-2353535#4691
  • 704Tainan CityTainan NorthNo.138,Sheng Li Road,Tainan, Taiwan

Recruiting Trial

867Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1738Cases

2020-04-01 - 2023-12-31

Phase III

Completed
Open-Label Randomised Controlled Trial of Efepoetin Alfa for Treatment of Anaemia Associated With Chronic Kidney Disease Patients Not on Dialysis (ND-CKD). A Non- Inferiority Trial Compared to Methoxy Polyethylene Glycol-Epoetin Beta (MIRCERA)

  • Condition/Disease

    Anaemia Associated With Chronic Kidney Disease

  • Test Drug

    Efepoetin alfa

Participate Sites
15Sites

Not yet recruiting8Sites

Recruiting1Sites

Terminated6Sites

2023-02-23 - 2026-10-31

Phase I

Active
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)

  • Condition/Disease

    Locally Advanced Solid Tumor、 Metastatic Solid Tumor

  • Test Drug

    NVL-520

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

2025-02-03 - 2029-12-23

Phase III

Not yet recruiting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination with Atezolizumab plus Bevacizumab Compared with Placebo plus Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Not Previously Treated with Systemic Therapy

  • Condition/Disease

    HCC

  • Test Drug

    TPST-1120

Participate Sites
6Sites

Recruiting6Sites

2023-03-01 - 2026-10-30

Phase I

Active
A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer

  • Condition/Disease

    HER2 Mutant Non-small Cell Lung Cancer

  • Test Drug

    膠囊劑 注射劑 注射劑

Participate Sites
5Sites

Recruiting5Sites

2023-05-01 - 2025-12-31

Phase I

Active
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors

  • Condition/Disease

    Solid Tumor

  • Test Drug

    錠劑 注射用凍晶粉末

Participate Sites
2Sites

Recruiting2Sites

2020-04-01 - 2025-01-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2019-05-01 - 2025-12-31

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2020-02-05 - 2026-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2024-02-01 - 2026-04-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-04-01 - 2026-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

1 4 5 6 7 8 174
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB